Citations

Clear

4847 citation(s) found for "Tu, Eric".

Do comorbid self-reported depression and anxiety influence outcomes following surgery for cervical spondylotic myelopathy?
Chan, Andrew K. , Shaffrey, Christopher I. , Park, Christine , Gottfried, Oren N., Than, Khoi D. , Bisson, Erica F. , Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Park, Paul , Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Michalopoulos, Giorgos D. , Sherrod, Brandon A. , Agarwal, Nitin , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V. , Michalopoulos, Giorgos

Mayo Clinic

Journal of Neurosurgery: Spine | March 31, 2023 | Volume: 39 | Issue: 1 | Pages: 11-27

10.3171/2023.2.spine22685 | PMID 37021762 Get It

OBJECTIVE Depression and anxiety are associated with inferior outcomes following spine surgery. In this study, the authors examined whether patients with cervical spondylotic myelopathy (CSM) who have both self-reported depression (SRD) and self-reported anxiety (SRA) have worse postoperative patient-reported outcomes (PROs) compared with patients who have only one or none of these comorbidities. METHODS This study is a retrospective analysis of prospectively collected data from the Quality Outcomes Database CSM cohort. Comparisons were made among patients who reported the following: 1) either SRD or SRA, 2) both SRD and SRA, or 3) neither comorbidity at baseline. PROs at 3, 12, and 24 months (scores for the visual analog scale [VAS] for neck pain and arm pain, Neck Disability Index [NDI], modified Japanese Orthopaedic Association [mJOA] scale, EQ-5D, EuroQol VAS [EQ-VAS], and North American Spine Society [NASS] patient satisfaction index) and achievement of respective PRO minimal clinically important differences (MCIDs) were compared. RESULTS Of the 1141 included patients, 199 (17.4%) had either SRD or SRA alone, 132 (11.6%) had both SRD and SRA, and 810 (71.0%) had neither. Preoperatively, patients with either SRD or SRA alone had worse scores for VAS neck pain (5.6 ± 3.1 vs 5.1 ± 3.3, p = 0.03), NDI (41.0 ± 19.3 vs 36.8 ± 20.8, p = 0.007), EQ-VAS (57.0 ± 21.0 vs 60.7 ± 21.7, p = 0.03), and EQ-5D (0.53 ± 0.23 vs 0.58 ± 0.21, p = 0.008) than patients without such disorders. Postoperatively, in multivariable adjusted analyses, baseline SRD or SRA alone was associated with inferior improvement in the VAS neck pain score and a lower rate of achieving the MCID for VAS neck pain score at 3 and 12 months, but not at 24 months. At 24 months, patients with SRD or SRA alone experienced less change in EQ-5D scores and were less likely to meet the MCID for EQ-5D than patients without SRD or SRA. Furthermore, patient self-reporting of both psychological comorbidities did not impact PROs at all measured time points compared with self-reporting of only one psychological comorbidity alone. Each cohort (SRD or SRA alone, both SRD and SRA, and neither SRD nor SRA) experienced significant improvements in mean PROs at all measured time points compared with baseline (p < 0.05). CONCLUSIONS Approximately 12% of patients who underwent surgery for CSM presented with both SRD and SRA, and 29% presented with at least one symptom. The presence of either SRD or SRA was independently associated with inferior scores for 3- and 12-month neck pain following surgery, but this difference was not significant at 24 months. However, at long-term follow-up, patients with SRD or SRA experienced lower quality of life than patients without SRD or SRA. The comorbid presence of both depression and anxiety was not associated with worse patient outcomes than either diagnosis alone.
Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain
Shanthanna, Harsha , Provenzano, David , Bouche, Bénédicte , Buchser, Eric, Chadwick, Raymond , Doshi, Tina L , Duarte, Rui , Hunt, Christine , Huygen, Frank , Knight, Judy, Kohan, Lynn , North, Richard B. , Winfree, Christopher J., Provenzano, David Anthony , Doshi, Tina L , Duarte, Rui , Hunt, Christine , Narouze, Samer , Shanthanna, Harsha , Eldabe, Sam S. , Rosenow, Joshua M. , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | March 31, 2023 | Volume: 48 | Issue: 6 | Pages: 273-287

10.1136/rapm-2022-104097 | PMID 37001888 Get It

Spinal cord stimulation (SCS) has demonstrated effectiveness for neuropathic pain. Unfortunately, some patients report inadequate long-term pain relief. Patient selection is emphasized for this therapy; however, the prognostic capabilities and deployment strategies of existing selection techniques, including an SCS trial, have been questioned. After approval by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine, a steering committee was formed to develop evidence-based guidelines for patient selection and the role of an SCS trial. Representatives of professional organizations with clinical expertize were invited to participate as committee members. A comprehensive literature review was carried out by the steering committee, and the results organized into narrative reports, which were circulated to all the committee members. Individual statements and recommendations within each of seven sections were formulated by the steering committee and circulated to members for voting. We used a modified Delphi method wherein drafts were circulated to each member in a blinded fashion for voting. Comments were incorporated in the subsequent revisions, which were recirculated for voting to achieve consensus. Seven sections with a total of 39 recommendations were approved with 100% consensus from all the members. Sections included definitions and terminology of SCS trial; benefits of SCS trial; screening for psychosocial characteristics; patient perceptions on SCS therapy and the use of trial; other patient predictors of SCS therapy; conduct of SCS trials; and evaluation of SCS trials including minimum criteria for success. Recommendations included that SCS trial should be performed before a definitive SCS implant except in anginal pain (grade B). All patients must be screened with an objective validated instrument for psychosocial factors, and this must include depression (grade B). Despite some limitations, a trial helps patient selection and provides patients with an opportunity to experience the therapy. These recommendations are expected to guide practicing physicians and other stakeholders and should not be mistaken as practice standards. Physicians should continue to make their best judgment based on individual patient considerations and preferences.
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
Morris, Michael J. , Hillman, David W. , Bobek, Olivia , Ryan, Charles J. , Antonarakis, Emmanuel S. , Bryce, Alan H. , Hahn, Olwen, Beltran, Himisha , Armstrong, Andrew J. , Schwartz, Lawrence B. , Langevin, Brooke , McGary, Eric C., Mehan, Paul, Goldkorn, Amir , Roth, Bruce J. , Xiao, Han , Watt, Colleen, Taplin, Mary‐Ellen , Halabi, Susan , Antonarakis, Emmanuel S. , Hillman, David W , Bobek, Olivia , Antonarakis, Emmanuel S , Bryce, Alan H , Beltran, Himisha , Armstrong, Andrew J , Beumer, Jan Hendrik , Goldkorn, Amir , Roth, Bruce J , Xiao, Han , Halabi, Susan , Small, Eric J , Morris, Michael J , Antonarakis, Emmanuel S , Heller, Glenn , Lewis, Lionel D. , Small, Eric J.

Mayo Clinic

Journal of Clinical Oncology | March 30, 2023 | Volume: 41 | Issue: 18 | Pages: 3352-3362

10.1200/jco.22.02394 | PMID 36996380 Get It

PURPOSE Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. PATIENTS AND METHODS Men with untreated mCRPC were randomly assigned (1:1) to receive first-line enzalutamide with or without AAP. The primary end point was OS. Toxicity, prostate-specific antigen declines, pharmacokinetics, and radiographic progression-free survival (rPFS) were also examined. Data were analyzed using an intent-to-treat approach. The Kaplan-Meier estimate and the stratified log-rank statistic were used to compare OS between treatments. RESULTS In total, 1,311 patients were randomly assigned: 657 to enzalutamide and 654 to enzalutamide plus AAP. OS was not statistically different between the two arms (median, 32.7 [95% CI, 30.5 to 35.4] months for enzalutamide v 34.2 [95% CI, 31.4 to 37.3] months for enzalutamide and AAP; hazard ratio [HR], 0.89; one-sided P = .03; boundary nominal significance level = .02). rPFS was longer in the combination arm (median rPFS, 21.3 [95% CI, 19.4 to 22.9] months for enzalutamide v 24.3 [95% CI, 22.3 to 26.7] months for enzalutamide and AAP; HR, 0.86; two-sided P = .02). However, pharmacokinetic clearance of abiraterone was 2.2- to 2.9-fold higher when administered with enzalutamide, compared with clearance values for abiraterone alone. CONCLUSION The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents resulting in increased abiraterone clearance may partly account for this result, although these interactions did not prevent the combination regimen from having more nonhematologic toxicity.
APOE and immunity: Research highlights
Kloske, Courtney M. , Barnum, Christopher J. , Batista, André F., Bradshaw, Elizabeth M. , Bu, Guojun , Dennison, Jessica , Gearon, Mary D, Goate, Alison , Haass, Christian , Hu, William T. , Huggins, Lenique , Jones, Nahdia S. , Liddelow, Shane A. , Marsh, Samuel E. , Petersen, Melissa, Piña‐Escudero, Stefanie Danielle , Reiman, Eric M. , Sexton, Claire E. , TCW, Julia , Wallings, Rebecca L. , Weninger, Stacie, Wharton, Whitney , Wishard, Tyler J. , Worley, Susan, Carrillo, María C. , Sexton, Claire , Bu, Guojun , Goate, Alison M , Hu, William T. , Brickman, Adam M. , Heneka, Michael T. , Koldamova, Radosveta P. , Lemere, Cynthia Ann , Marcora, Edoardo , Nielsen, Henrietta M. , Petersen, Kellen K. , Petersen, Melissa , Qiu, Wei Qiao , Quiroz, Yakeel T. , Tansey, Malú G. , Teunissen, Charlotte E. , Tijms, Betty M. , Kant, Rik van der , Wilcock, Donna M. , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | March 28, 2023 | Volume: 19 | Issue: 6 | Pages: 2677-2696

10.1002/alz.13020 | PMID 36975090 Get It

AbstractINTRODUCTIONAt the Alzheimer's Association's APOE and Immunity virtual conference, held in October 2021, leading neuroscience experts shared recent research advances on and inspiring insights into the various roles that both the apolipoprotein E gene (APOE) and facets of immunity play in neurodegenerative diseases, including Alzheimer's disease and other dementias.METHODSThe meeting brought together more than 1200 registered attendees from 62 different countries, representing the realms of academia and industry.RESULTSDuring the 4‐day meeting, presenters illuminated aspects of the cross‐talk between APOE and immunity, with a focus on the roles of microglia, triggering receptor expressed on myeloid cells 2 (TREM2), and components of inflammation (e.g., tumor necrosis factor α [TNFα]).DISCUSSIONThis manuscript emphasizes the importance of diversity in current and future research and presents an integrated view of innate immune functions in Alzheimer's disease as well as related promising directions in drug development.
Whole Genome Analysis of Venous Thromboembolism: the Trans-Omics for Precision Medicine Program
Seyerle, Amanda A. , Laurie, Cecelia , Coombes, Brandon J. , Jain, Deepti , Conomos, Matthew P. , Brody, Jennifer A. , Chen, Ming‐Huei , Gogarten, Stephanie M. , Beutel, Kathleen M , Gupta, Namrata , Heckbert, Susan R. , Jackson, Rebecca D., Johnson, Andrew D. , McKnight, Barbara, Metcalf, Ginger , Morrison, Alanna C. , Reiner, Alex P. , Sofer, Tamar , Tang, Weihong , Program, Trans-Omics for Precision Medicine, Boerwinkle, Eric , Gabriel, Stacey , Gibbs, Richard A. , Laurie, Cathy C. , Rice, Kenneth , Pankow, James S. , Smith, Nicholas L. , Laurie, Cecelia A , Ko, Darae , Manson, JoAnn E , Metcalf, Ginger A , Morrison, Alanna C , Reiner, Alexander P , Sofer, Tamar , Tang, Weihong , Wiggins, Kerri L , Boerwinkle, Eric , de Andrade, Mariza , Laurie, Cathy C , Psaty, Bruce M , Vasan, Ramachandran S , Rice, Ken , Kooperberg, Charles , Pankow, James S , Smith, Nicholas L , Pankratz, Nathan , Brody, Jennifer A , Coombes, Brandon J , Rice, Kenneth , Manson, JoAnn E. , Wiggins, Kerri L. , Program, Trans-Omics for Precision Medicine, Andrade, Mariza de , Psaty, Bruce M. , Vasan, Ramachandran S. , Kooperberg, Charles , Pankratz, Nathan

Mayo Clinic

Circulation: Genomic and Precision Medicine | March 24, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.121.003532 | PMID 36960714 Get It

Background: Risk for venous thromboembolism has a strong genetic component. Whole genome sequencing from the TOPMed program (Trans-Omics for Precision Medicine) allowed us to look for new associations, particularly rare variants missed by standard genome-wide association studies. Methods: The 3793 cases and 7834 controls (11.6% of cases were individuals of African, Hispanic/Latino, or Asian ancestry) were analyzed using a single variant approach and an aggregate gene-based approach using our primary filter (included only loss-of-function and missense variants predicted to be deleterious) and our secondary filter (included all missense variants). Results: Single variant analyses identified associations at 5 known loci. Aggregate gene-based analyses identified only PROC (odds ratio, 6.2 for carriers of rare variants; P =7.4×10 −14 ) when using our primary filter. Employing our secondary variant filter led to a smaller effect size at PROC (odds ratio, 3.8; P =1.6×10 −14 ), while excluding variants found only in rare isoforms led to a larger one (odds ratio, 7.5). Different filtering strategies improved the signal for 2 other known genes: PROS1 became significant (minimum P =1.8×10 −6 with the secondary filter), while SERPINC1 did not (minimum P =4.4×10 −5 with minor allele frequency <0.0005). Results were largely the same when restricting the analyses to include only unprovoked cases; however, one novel gene, MS4A1 , became significant ( P =4.4×10 −7 using all missense variants with minor allele frequency <0.0005). Conclusions: Here, we have demonstrated the importance of using multiple variant filtering strategies, as we detected additional genes when filtering variants based on their predicted deleteriousness, frequency, and presence on the most expressed isoforms. Our primary analyses did not identify new candidate loci; thus larger follow-up studies are needed to replicate the novel MS4A1 locus and to identify additional rare variation associated with venous thromboembolism.
Esthesioneuroblastoma: The Fate of Patients with Recurrence
Iyoha, Ehiremen, Link, Michael J., Peris-Ceyda, Maria, Moore, Eric J. , Stokken, Janalee K., Gamez, Mauricio E. , Ni, Garrett , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Choby, Garret

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762162 Get It

Examining the Natural History and Patterns of Disease Recurrence in Patients with Positive Margin Esthesioneuroblastoma
Bauman, Megan M., Graves, Jeffrey P., Haller, Travis J. , McMillan, Ryan A. , Moore, Eric J. , Link, Michael J., Choby, Garret , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762048 Get It